University Health Network
Latest From University Health Network
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.